^
    Back
    Association details:
    Biomarker:KDM6A mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2023
    Title:

    Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).

    Published date:
    02/13/2023
    Excerpt:
    Among 152 mUC ICI-treated pts, 107 had NGS data (FoundationOne, UCSF500, Strata), including 85 with TMB data….Inferior outcomes were seen in pts with CDKN2B, KDM6A, FGF3, FGF4, and FGF19 alterations (Table).
    DOI:
    10.1200/JCO.2023.41.6_suppl.532